TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00023868
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04415983
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Klacid twice daily
Study: NCT04415983
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazoe twice daily
Study: NCT00023868
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023868
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00023868
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03384277
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
Study: NCT03384277
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
Study: NCT04664803
Drug: Cefecin Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04664803
Drug: Omnicef Cap.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00926627
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical preparation as the study drug, but without the active substance, administered b.i.d.
Study: NCT00862394
Drug: Foster
Normalized name: Foster and Thrive Biotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
Study: NCT00862394
Drug: Foster
Normalized name: Foster and Thrive Biotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
Study: NCT00031876
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00964964
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected s.c. (under the skin) four times weekly
Study: NCT00295165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously once daily
Study: NCT03480308
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Study: NCT03534284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pill manufactured to mimic trazodone tablets.
Study: NCT00372645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00830765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
Study: NCT02122055
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
Study: NCT00264147
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
Study: NCT00264147
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
Study: NCT00264147
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
Study: NCT00264147
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Study: NCT00264147
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
Study: NCT00264147
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Study: NCT00264147
Drug: Comparator: diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
Study: NCT03717103
Drug: IBI188
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
Study: NCT01100502
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 21 days by IV infusion
Study: NCT00248482
Drug: Gleevec™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
Study: NCT04039724
Drug: HCP0605 + HGP0816
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04039724
Drug: HCP1305
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828711
Drug: MVI 100
Normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT00828711
Drug: MVI 150
Normalized name: Briumvi 150 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT00828711
Drug: MVI 200
Normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT01843127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00095498
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous injection
Study: NCT03274167
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01494636
Drug: GSK2339345 (solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
Study: NCT01494636
Drug: GSK2339345 (nebulised)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
Study: NCT00555724
Drug: BIIB022
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion once every three weeks until disease progression or unacceptable toxicity
Study: NCT01094210
Drug: Fluorides, Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
Study: NCT02648490
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
Study: NCT02981979
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: used in control group during the induced remission therapy for 24 weeks.
Study: NCT03040401
Drug: Cohort 1, Ceplene® and Proleukin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study: NCT03040401
Drug: Cohort 2, Ceplene® and Proleukin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study: NCT03040401
Drug: Cohort 3, Ceplene® and Proleukin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study: NCT00143338
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00593294
Drug: OC - Drospirenone plus Ethynylestradiol
Normalized name: drospirenone and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
Study: NCT03407937
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
Study: NCT02664142
Drug: Anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
Study: NCT03720678
Drug: mFOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
Study: NCT03054428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
Study: NCT02877238
Drug: Total intravenous anesthesia plus remote ischemic preconditioning
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
Study: NCT04356937
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)
Study: NCT01265498
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule, 25 mg daily for 72 weeks
Study: NCT00061984
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02476097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
Study: NCT00884520
Drug: [F-18] VM4-037
Approvals — FDA: no, EMA: no, PMDA: no
Description: The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
Study: NCT02932566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
Study: NCT02516332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03092752
Drug: oral antidiabetic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: OADs usage conditions and dose selection in T2DM patients
Study: NCT03706261
Drug: 18F-MK-6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 5 mCi of 18F-MK-6240 for tau PET.
Study: NCT04383730
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
Study: NCT00987636
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h
Study: NCT00471484
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00471484
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00709332
Drug: Norgestimate; Ethinyl Estradiol; Folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01951508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os
Study: NCT03533751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT02791867
Drug: AphoelineBrake
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
Study: NCT00223704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
Study: NCT02028598
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral single dose administration
Study: NCT02028598
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral single dose administration
Study: NCT00419536
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05418803
Drug: YHP1807 Tab. 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5mg
Study: NCT05418803
Drug: YHR1901 Tab. 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5mg
Study: NCT01591161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of vehicle into the study eye QID for 14 days.
Study: NCT02540928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03620513
Drug: Anesthesia (Lidocaine 15%)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in arm/group
Study: NCT03620513
Drug: Decongestants and Anesthesia (oxymetazoline and lidocaine)
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in arm/group
Study: NCT03620513
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray of normal saline as premedication
Study: NCT01553773
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
Study: NCT04481139
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302, oral, once daily
Study: NCT04481139
Drug: SHR0302 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 placebo, oral, once daily
Study: NCT04650737
Drug: single shot ESBP with dexmedtomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
Study: NCT04650737
Drug: continous ESPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
Study: NCT00103285
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00103285
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or IT
Study: NCT00103285
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00103285
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00103285
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IM or IT
Study: NCT01278758
Drug: ASA404, DMXAA or DXAA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00041548
Drug: nitric oxide for inhalation
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: given at 20 ppm for 1 hour then weaned off over 4 hours
Study: NCT00150176
Drug: Placebo - Double Blind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
Study: NCT02169219
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week
Study: NCT00689585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg matching placebo capsules
Study: NCT03220841
Drug: Thiopurine
Normalized name: Thiopurine methyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose optimized thiopurine
Study: NCT01386606
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical gel~1X a day 6 weeks
Study: NCT02176213
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low dose cyclophosphamide 50 mg PO BID x 21 days
Study: NCT00398125
Drug: GSK364735
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04472819
Drug: SHR2285 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose or multi-dose
Study: NCT04472819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose or multi-dose
Study: NCT04371185
Drug: BAT2206
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
Study: NCT01764685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03646591
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
Study: NCT01015339
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Study: NCT04591639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
Study: NCT02233543
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered once daily via single-dose dry powder inhaler